AIM: To clarify the effectiveness and safety of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the diagnosis of pancreatic cancer (PC). METHODS: Patients who were diagnosed with unresectable, locally advanced or metastatic PC between February 2006 and September 2011 were selected for this retrospective study. FNA biopsy for pancreatic tumors had been performed percutaneously under extracorporeal ultrasound guidance until October 2009; then, beginning in November 2009, EUS-FNA has been performed. We reviewed the complete medical records of all patients who met the selection criteria for the following data: sex, age, location and size of the targeted tumor, histological and/or cytological findings, details of puncture procedures, time from day of puncture until day of definitive diagnosis, and details of severe adverse events. RESULTS: Of the 121 patients who met the selection criteria, 46 had a percutaneous biopsy (Group A) and 75 had an EUS-FNA biopsy (Group B). Adequate cytological specimens were obtained in 42 Group A patients (91.3%) and all 75 Group B patients (P = 0.0192), and histological specimens were obtained in 41 Group A patients (89.1%) and 65 Group B patients (86.7%). Diagnosis of malignancy by cytology was positive in 33 Group A patients (78.6%) and 72 Group B patients (94.6%) (P = 0.0079). Malignancy by both cytology and pathology was found in 43 Group A (93.5%) and 73 Group B (97.3%) patients. The mean period from the puncture until the cytological diagnosis in Group B was 1.7 d, which was significantly shorter than that in Group A (4.1 d) (P < 0.0001). Severe adverse events were experienced in two Group A patients (4.3%) and in one Group B patient (1.3%). CONCLUSION: EUS-FNA, as well as percutaneous needle aspiration, is an effective modality to obtain cytopathological confirmation in patients with advanced PC.
AIM: To clarify the effectiveness and safety of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the diagnosis of pancreatic cancer (PC). METHODS:Patients who were diagnosed with unresectable, locally advanced or metastatic PC between February 2006 and September 2011 were selected for this retrospective study. FNA biopsy for pancreatic tumors had been performed percutaneously under extracorporeal ultrasound guidance until October 2009; then, beginning in November 2009, EUS-FNA has been performed. We reviewed the complete medical records of all patients who met the selection criteria for the following data: sex, age, location and size of the targeted tumor, histological and/or cytological findings, details of puncture procedures, time from day of puncture until day of definitive diagnosis, and details of severe adverse events. RESULTS: Of the 121 patients who met the selection criteria, 46 had a percutaneous biopsy (Group A) and 75 had an EUS-FNA biopsy (Group B). Adequate cytological specimens were obtained in 42 Group A patients (91.3%) and all 75 Group B patients (P = 0.0192), and histological specimens were obtained in 41 Group A patients (89.1%) and 65 Group B patients (86.7%). Diagnosis of malignancy by cytology was positive in 33 Group A patients (78.6%) and 72 Group B patients (94.6%) (P = 0.0079). Malignancy by both cytology and pathology was found in 43 Group A (93.5%) and 73 Group B (97.3%) patients. The mean period from the puncture until the cytological diagnosis in Group B was 1.7 d, which was significantly shorter than that in Group A (4.1 d) (P < 0.0001). Severe adverse events were experienced in two Group A patients (4.3%) and in one Group B patient (1.3%). CONCLUSION: EUS-FNA, as well as percutaneous needle aspiration, is an effective modality to obtain cytopathological confirmation in patients with advanced PC.
Authors: Sukru Mehmet Erturk; Koenraad J Mortelé; Kemal Tuncali; John R Saltzman; Roger Lao; Stuart G Silverman Journal: AJR Am J Roentgenol Date: 2006-12 Impact factor: 3.959
Authors: John David Horwhat; Erik K Paulson; Kevin McGrath; M Stanley Branch; John Baillie; Douglas Tyler; Theodore Pappas; Robert Enns; Gail Robuck; Helen Stiffler; Paul Jowell Journal: Gastrointest Endosc Date: 2006-06 Impact factor: 9.427
Authors: M Di Stasi; R Lencioni; L Solmi; F Magnolfi; E Caturelli; I De Sio; A Salmi; L Buscarini Journal: Am J Gastroenterol Date: 1998-08 Impact factor: 10.864
Authors: Alan D Savoy; Massimo Raimondo; Timothy A Woodward; Kyung Noh; Surakit Pungpapong; Arthur D Jones; Julia Crook; Michael B Wallace Journal: Gastrointest Endosc Date: 2007-06 Impact factor: 9.427
Authors: John DeWitt; Benedict Devereaux; Melissa Chriswell; Kathleen McGreevy; Thomas Howard; Thomas F Imperiale; Donato Ciaccia; Kathleen A Lane; Dean Maglinte; Kenyon Kopecky; Julia LeBlanc; Lee McHenry; James Madura; Alex Aisen; Harvey Cramer; Oscar Cummings; Stuart Sherman Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: M Benavides; A Abad; I Ales; A Carrato; E Díaz Rubio; J Gallego; J García-Foncillas; C Grávalos; B Laquente; C Pericay; F Rivera; J Tabernero; E Aranda Journal: Clin Transl Oncol Date: 2014-04-12 Impact factor: 3.405